NCT07490067 Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
| NCT ID | NCT07490067 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Michigan |
| Condition | Heart Failure With Reduced Ejection Fraction |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-07 |
| Primary Completion | 2029-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2026-07 with a primary completion date of 2029-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics. Participants will have the beta-blocker (BB) polygenic score calculated from genotype data. The score will be used to stratify the patients in the low and high polygenic score groups in the study. The hypotheses for this trial are: * HFrEF patients with high polygenic score will have weaker cardiovascular responses to metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score have lower steady-state plasma concentrations of metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score require higher metoprolol succinate plasma concentrations to achieve similar cardiovascular effects as those with low polygenic score.
Eligibility Criteria
Inclusion Criteria: * Heart Failure with Reduced Ejection Fraction (HFrEF) * Has not taken a beta-blocker within the past 6 months (preferred), or if needed to meet enrollment target, patients that have not taken a beta-blocker in the past 3 months, or only taken a low dose of beta-blocker within the past 6 months (i.e., \< 50% of the guideline-recommended HFrEF target dose, or for beta-blockers that are not approved for HFrEF, \<50% of the maximum dose) * Genetic data already available to calculate the polygenic score (e.g., through participation in the Michigan Genomics Initiative (MGI) or other genetic tests) or willingness to provide a deoxyribonucleic acid (DNA) sample for genetic analysis * White race * Has been prescribed a stable dose (including no dose) of angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), ARB-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 (SGLT-2) inhibitor, or mineralocorticoid receptor antagonist (MRA) for at least the past 4 weeks * Has been prescribed a stable dose (including no dose) of diuretic(s) for at least the past 2 weeks * For women of child-bearing potential: the participant is willing to perform a pregnancy test and use a highly effective contraceptive method for at least 4 weeks prior to the start of metoprolol treatment, during the entire metoprolol treatment period, and for at least 5 days after the discontinuation of metoprolol treatment * Ability to understand and willing to sign a written informed consent Exclusion Criteria: * Prior heart transplant or left ventricular assist device (LVAD) or planned within treatment period * Planned implantation of a pacemaker or Cardiac Resynchronization Therapy (CRT) during treatment period * Patients with a pacemaker that does not allow their heart rate to change in response to exercise per protocol * Pregnant * Systolic blood pressure \< 95 millimeters of mercury (mmHg) * Heart rate \< 60 beats per minute * Second (Mobitz II)- or third-degree heart block * Cardiogenic shock * Patients with acute decompensated heart failure requiring current hospitalization or immediate medical intervention. * Sick sinus syndrome * Pheochromocytoma * Known hypersensitivity to the metoprolol succinate oral tablet used in the trial * Hypertrophic obstructive cardiomyopathy * Active myocarditis * Acute coronary syndrome within the past month * Active or uncorrected severe mitral or aortic valvular dysfunction * Patients with known severe congenital heart disease per protocol * Child-Pugh Class C liver disease * Patients with end-stage renal disease (ESRD) requiring hemodialysis * Concomitant disease that prohibits participating in Cardiopulmonary Exercise Test (CPET) per protocol * Concomitant disease with expected survival less than the duration of the study (e.g., metastatic cancer) * Current or planned treatment with cardiotoxic medications, including interferons and the cancer therapies per protocol * Concurrent participation in another clinical trial that may affect participant safety or validity of data collected in this clinical trial * Inability to take oral medication * Unwilling or unlikely to adhere to the study procedures, as determined at the discretion of the study team, including but not limited to the following reasons: 1. Psychiatric illness or other comorbidities 2. Substance abuse 3. Social or logistical circumstances
Contact & Investigator
Jasmine Luzum, PharmD, PhD
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT07490067 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure With Reduced Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07490067 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07490067 currently recruiting?
Yes, NCT07490067 is actively recruiting participants. Contact the research team at diamthom@med.umich.edu for enrollment information.
Where is the NCT07490067 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT07490067 clinical trial?
NCT07490067 is sponsored by University of Michigan. The principal investigator is Jasmine Luzum, PharmD, PhD at University of Michigan. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.